Výsledky vyhledávání - "Yuichi Mikamoto"

Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)

Autor: Takashi Kojima, Masako Asayama, Yosuke Togashi, Yuichi Mikamoto, Naoki Takahashi, Masashi Wakabayashi, Akihito Kawazoe, Hitomi Tamura, Nami Hirano, Shota Fukuoka, Akihiro Sato, Takeshi Kuwata, Kohei Shitara, Takako Yoshii, Shogo Nomura, Hiroyoshi Nishikawa, Daisuke Kotani, Hiroki Hara

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(18)

PURPOSE This is a phase Ib trial of regorafenib plus nivolumab for gastric and colorectal cancer. PATIENTS AND METHODS Enrolled patients received regorafenib plus nivolumab in a dose-finding part to estimate the maximum tolerated dose. Additional pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c1dd87d832f6e56032b18e7380fbff3
https://pubmed.ncbi.nlm.nih.gov/32398704

Zobrazit plný text záznamu

Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial

Autor: Shota Fukuoka, Yoshiaki Nakamura, Tsukiko Higuchi, Yasutoshi Kuboki, Masashi Wakabayashi, Kohei Shitara, Hikari Shima, Yuichi Mikamoto, Akihito Kawazoe, Akihiro Sato, Takeshi Kuwata, Shogo Nomura, Noriko Fujishiro

Publikováno v: The Lancet. Oncology. 21(8)

Summary Background Pembrolizumab, an anti-PD-1 antibody, results in tumour response in around 15% of patients with advanced gastric cancer who have a PD-L1 combined positive score of at least 1. Lenvatinib, a multikinase inhibitor of VEGF receptors a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e03796e585588ff1ae5d784fbe4d0da
https://pubmed.ncbi.nlm.nih.gov/32589865

Zobrazit plný text záznamu

An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706)

Autor: Shota Fukuoka, Yuichi Mikamoto, Noriko Fujishiro, Akihito Kawazoe, Tsukiko Higuchi, Yoshiaki Nakamura, Yasutoshi Kuboki, Akihiro Sato, Masashi Wakabayashi, Kohei Shitara, Shogo Nomura, Hikari Shima

Publikováno v: Journal of Clinical Oncology. 38:374-374

374 Background: Pembrolizumab, anti–PD-1 antibody, provides response rates of around 15% in patients (pts) with PD-L1-positive advanced gastric cancer (AGC). Lenvatinib, a multikinase inhibitor of VEGF receptors and other receptor tyrosine kinases,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::13cd7f9c4e509847dcb56053e3937d20
https://doi.org/10.1200/jco.2020.38.4_suppl.374

Zobrazit plný text záznamu

Scoop: Multicenter phase I/II trial of BBI608 and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503)

Autor: Yasutoshi Kuboki, Hiroyoshi Nishikawa, Takayuki Yoshino, Shogo Nomura, Satoshi Yuki, Eiji Shinozaki, Yosuke Togashi, Akihiro Sato, Tomohiro Nishina, Hiroki Hara, Yoshito Komatsu, Atsushi Ohtsu, Yuichi Mikamoto, Nami Hirano, Akihito Kawazoe, Koji Takahashi

Publikováno v: Journal of Clinical Oncology. 38:107-107

107 Background: The anti–PD-1 antibody pembrolizumab (P) provides response rates of 28-57% in patients (pts) with MSI-H metastatic colorectal cancer (mCRC) vs 0% in those with non-MSI-H cancers. STAT3 has been previously reported as a potential key

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad68e5a0459e6c7b519f485158b366f3
https://doi.org/10.1200/jco.2020.38.4_suppl.107

Zobrazit plný text záznamu

Updated results from a phase Ib trial of regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer (REGONIVO, EPOC1603)

Autor: Takashi Kojima, Hitomi Tamura, Masashi Wakabayashi, Yuichi Mikamoto, Hiroyoshi Nishikawa, Akihito Kawazoe, Kohei Shitara, Takako Yoshii, Shogo Nomura, Nami Hirano, Naoki Takahashi, Shota Fukuoka, Akihiro Sato, Masako Asayama, Hiroki Hara, Daisuke Kotani

Publikováno v: Journal of Clinical Oncology. 38:135-135

135 Background: In the phase 1 REGONIVO study, regorafenib of 80 mg/day plus nivolumab showed manageable safety profiles and encouraging anti-tumor activity for advanced colorectal cancer (CRC) or gastric cancer (GC) with objective response rate (ORR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::54f007e4f6c46f7c443d830fb24118f7
https://doi.org/10.1200/jco.2020.38.4_suppl.135

Zobrazit plný text záznamu

Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)

Autor: Hiroyoshi Nishikawa, Takashi Kojima, Yuichi Mikamoto, Shogo Nomura, Akihito Kawazoe, Takako Yoshii, Kohei Shitara, Akihiro Sato, Hitomi Tamura, Yosuke Togashi, Daisuke Kotani, Ayako Sugama, Naoki Takahashi, Masako Asayama, Shota Fukuoka, Masashi Wakabayashi, Hiroki Hara

Publikováno v: Journal of Clinical Oncology. 37:2522-2522

2522 Background: Immune suppressive cells such as regulatory T cells (Tregs) or tumor-associated macrophages (TAMs) may contribute to resistance to anti-PD-1/PD-L1 inhibitors (A-PD1). Regorafenib, a potent inhibitor of angiogenic and oncogenic kinase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::63f5391b0461bed7ace1847cb1b9bffa
https://doi.org/10.1200/jco.2019.37.15_suppl.2522

Zobrazit plný text záznamu

Regorafenib and nivolumab combination therapy for advanced and metastatic solid tumors: Phase I clinical trial (EPOC1603)

Autor: Akihiro Sato, Hitomi Tamura, Satoshi Shimizu, Miki Fukutani, Shogo Nomura, Shota Fukuoka, Masafumi Ikeda, Masashi Wakabayashi, Kohei Shitara, Hiroki Hara, Yuichi Mikamoto, Hideaki Takahashi

Publikováno v: Journal of Clinical Oncology. 36:TPS3124-TPS3124

TPS3124Background: Immune checkpoint inhibitors (CPIs) have shown promising efficacies in several types of malignancies. However, still around half of patients with most tumor types experienced dis...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7f7a2e936f6378b1b0e1e101f9bad0ff
https://doi.org/10.1200/jco.2018.36.15_suppl.tps3124

Zobrazit plný text záznamu

Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503

Publikováno v: Journal of Clinical Oncology. 36:3530-3530

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9a6baf7898dcefaf89830986a12d1e0
https://doi.org/10.1200/jco.2018.36.15_suppl.3530

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání